CARDAMYST Brings FDA-Approved Self-Care to Paroxysmal Tachycardia Patients

Milestone Pharmaceuticals has achieved a significant milestone with the U.S. launch of CARDAMYST, marking the first and only FDA-approved self-administered therapy for adults experiencing paroxysmal tachycardia. This groundbreaking nasal spray is now available through retail pharmacies nationwide, transforming how millions of Americans manage sudden heart rhythm episodes.

Understanding Paroxysmal Tachycardia: A Widespread Condition

Paroxysmal supraventricular tachycardia (PSVT), commonly known as paroxysmal tachycardia, affects over two million Americans and ranks among the most common cardiac rhythm disorders. The condition occurs when an electrical abnormality in the heart triggers sudden episodes of rapid heartbeat, typically accelerating to 160-220 beats per minute. These episodes strike unpredictably, creating alarming symptoms including heart palpitations, sweating, chest pressure, difficulty breathing, and severe anxiety. Younger adults and highly active individuals face increased risk, as vigorous physical activity frequently triggers these episodes. Beyond the immediate physical discomfort, paroxysmal tachycardia significantly impacts daily life, forcing patients to limit activities and manage constant anxiety about the next attack.

How CARDAMYST Transforms Acute Episode Management

CARDAMYST (etripamil nasal spray) represents a paradigm shift in paroxysmal tachycardia treatment. As a rapid-acting calcium channel blocker formulated for on-demand use, the therapy enables patients to regain control during acute episodes without emergency room intervention. For over 30 years, doctors relied exclusively on intravenous adenosine administered in hospital settings—a limitation that confined patients to emergency departments during crises. CARDAMYST dismantles this barrier by delivering immediate relief in any setting: home, workplace, or community. The nasal spray’s convenience and rapid action address a critical gap in patient care, allowing individuals to interrupt episodes at their onset rather than endure prolonged suffering.

Expanding Patient Access Through Support Programs

Milestone has engineered comprehensive patient support infrastructure to ensure broad accessibility. The initiative includes benefits verification services, insurance reimbursement coordination, and copay assistance programs. Commercially insured eligible patients will see copays capped at $25, dramatically reducing financial barriers to treatment. The company continues negotiating with insurers on coverage policies and formulary placement, aiming to maximize patient accessibility across diverse insurance landscapes. These support mechanisms recognize that breakthrough therapies deliver value only when patients can actually access them.

Market Reception and Future Implications

The launch positions Milestone Pharmaceuticals at a pivotal transition point from a clinical-stage developer to an established commercial entity. Market response has reflected measured sentiment, with MIST stock trading at $1.93, fluctuating within its recent range of $0.62 to $3.06 over the past twelve months. CARDAMYST’s introduction heralds a broader transformation in cardiac arrhythmia management, potentially reshaping treatment protocols and patient outcomes for those living with paroxysmal tachycardia. The availability of this self-administered option may encourage earlier intervention, reduce emergency hospitalizations, and fundamentally enhance quality of life for millions of Americans managing this condition.